by Andrea Lobo | Feb 13, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Novocure’s Optune Pax, a type of Tumor Treating Fields (TTFields) therapy, as a treatment for locally advanced pancreatic cancer. The approval specifically covers the use of Optune Pax in combination with the...
by MM360 Staff | Feb 13, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Feb 13, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by Marisa Wexler, MS | Feb 12, 2026 | Myeloma News
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning the study from a Phase 2 to a pivotal Phase 3 trial. “Following discussions with regulatory agencies,...
by Marisa Wexler, MS | Feb 11, 2026 | Myeloma News
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel, known for short as lira-cel, lived longer than they were expected to, according to new data announced by developer...
